| abstract |
The invention relates to a method of administering pirfenidone to a patient in need thereof, comprising discontinuing the concomitant use or concurrent administration of fluvoxamine to avoid unwanted drug interactions with fluvoxamine in a patient receiving pirfenidone, wherein pirfenidone is administered to the patient in a total daily dose of about 1800 mg, or about 2400 mg, or approximately 2403 mg. Pirfenidone is administered to the patient three times a day with meals. The method of administering pirfenidone to a patient includes reducing the dose of pirfenidone in patients receiving fluvoxamine to a total daily dose of 801 mg / day. In this method, fluvoxamine is canceled within 1 month before starting pirfenidone therapy. Fluvoxamine can be discontinued within 2 weeks prior to starting pirfenidone therapy. The method relates to the treatment of idiopathic pulmonary fibrosis (IPF) and myocardial fibrosis, musculoskeletal fibrosis, pancreatic fibrosis, liver fibrosis, renal fibrosis, fibrous vascular disease or scleroderma. |